Latest Gonadotropin-releasing hormone antagonist Stories
MIAMI, Jan. 18, 2013 /PRNewswire/ -- Biscayne Pharmaceuticals, Inc. today announced that it has closed a $1.5 million financing. The new company is developing novel growth hormone-releasing hormone (GHRH) drugs based on recent discoveries by the company's scientific advisor, Dr. Andrew V. Schally, a world-renowned drug researcher and Nobel laureate who pioneered the field of hypothalamic peptide drugs. Biscayne also announced that it has exclusively licensed intellectual...
Women with uterine fibroids larger than 10 cm have a new nonsurgical treatment choice –hormone acting drugs followed by uterine artery embolization, a new study shows. The new treatment option can replace hysterectomy, which leaves women infertile. The study, conducted at the Yonsei University College of Medicine in Seoul South Korea, included 40 women with 10 cm or larger uterine fibroids. Twelve of the women received gonadotropin-releasing hormone (GnRH) agonists to shrink their...
LAUSANNE, Switzerland, July 24, 2012 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced the treatment of its first patient in a multicentre, open, non-comparative Phase III study to investigate the efficacy, safety, and pharmacokinetics of two subcutaneous (SC) injections of Debio 8206...
ABBOTT PARK, Ill., June 5, 2012 /PRNewswire/ -- Abbott (NYSE: ABT), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the initiation of a pivotal Phase 3 clinical trial designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis. Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist. "Endometriosis can be a debilitating disease that affects millions of women around the world and the exploration of...
SAN DIEGO, Sept. 27, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that an elagolix podium presentation has been accepted for the scientific program at the 2011 Annual Meeting of the American Society for Reproductive Medicine, to be held October 15-19, 2011 in Orlando, Florida. This annual meeting draws over 4,000 experts from around the world to address current topics related to human reproduction. "We are very pleased to participate in the annual...
SAN DIEGO, June 16, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that three elagolix presentations have been accepted for the scientific program at 2011 World Congress on Endometriosis, to be held September 4-7, 2011 in Montpellier, France. This important meeting is sponsored by the World Endometriosis Society and occurs every three years, bringing together clinicians and basic scientists from all over the world to share the latest developments in...
Gonadotrophin-releasing hormone antagonists as effective as agonists with fewer serious harmful effectsWith new information available, authors of a Cochrane Systematic Review have revised their conclusions about the relative effectiveness of two different treatments used to help women become pregnant. They now conclude that giving women gonadotrophin-releasing hormone (GnRH) antagonists leads to similar live-birth rates compared with GnRH agonists. Previously they had concluded that women who...
(Ivanhoe Newswire) -- Giving women gonadotrophin-releasing hormone (GnRH) antagonists leads to similar live-birth rates compared with GnRH agonists, according to a new study. Previous research had concluded that women who used antagonists tended to have lower birth-rates than those using agonists.This is important because the research also showed that GnRH antagonists can halve the risk of over-stimulating the ovaries compared with GnRH agonists, as well as halving the number of women who...
ABBOTT PARK, Ill. and SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be...
SAN FRANCISCO, June 1 /PRNewswire/ -- FIRMAGON® (degarelix for injection) resulted in fast, long-term suppression of testosterone in prostate cancer patients, without an initial testosterone surge or microsurge, and rapidly reduced prostate-specific antigen (PSA) levels, according to a review of data presented here today at the AUA 2010 annual meeting by Dr. Judd Moul, Chief of the Division of Urology at Duke University Health Science Center. Dr. Moul was joined at the symposia by Dr....
